Base-Mediated Aerobic Oxidation of Hagemann's Ester: Competitive Hydroxylation at C-1 and C-3 Positions

Sung Hwan Kim, Hyun Seung Lee, Bo Ram Park, and Jae Nyoung Kim*

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea *E-mail: kimjn@chonnam.ac.kr Received February 13, 2011, Accepted March 2, 2011

Key Words : Aerobic oxidation, Hagemann's ester, Hydroxylation, Catechol

The Hagemann's ester (Fig. 1) has been extensively used for the synthesis of various complex compounds.^{1,2} The reason might be due to its highly-functionalized nature and ready availability.^{1,2} The reaction of Hagemann's ester and an electrophile can occur theoretically at C-1, C-3, C-5, and C-2' positions (Fig. 1). As an example, however, it has been generally accepted that the site preference for alkylation was C-3, the resulting C-3-alkyl derivatives often being accompanied by small amounts of the C-1-alkyl products.^{1a} Although the Hagemann's ester could be air-oxidized to poly-substituted phenol or catechol derivatives, a small piece of work has been reported,³ to the best of our knowledge. Irie and co-workers examined an aerobic oxidation under the influence of KF/DMSO/O2 at 60 °C to obtain C-1 oxidation product (62%) along with a trace amount of C-3 oxidation product (1%).^{3a} Stoodley and co-workers obtained a C-1 oxidation product only under the influence of excess amounts of activated charcoal (3 days, reflux, 50%).^{3b}

Recently, we have synthesized many interesting compounds using an aerobic oxidation under the influence of a base such as DBU and K₂CO₃.⁴ Meantime we decided to examine the aerobic oxidation of Hagemann's ester under basic conditions. We imagined that C-1 oxidation would produce either **3a** or **4a**, while **2a** could be produced by C-3 oxidation, as shown in Scheme 1. Thus we prepared compound **1a** from benzaldehyde and methyl acetoacetate according to the reported procedure as a *cis/trans* mixture (*ca.* 1:8),^{1b,1e,2c,2h} and examined an aerobic oxidation. Initial experiment of **1a** with K_2CO_3/DMF under O_2 balloon atmosphere produced **2a** (25%) and **3a** (35%) in moderate yields. We could not obtain a phenol derivative **4a** at all. Aerobic oxidation of **1a**, most likely *via* the carbanion intermediate **I**, would produce **II** and **3a**. The intermediate **II** was converted to a catechol derivative **2a** by tautomerization and concomitant aerobic oxidation.

The ratio of 2a/3a as well as the combined yields could be improved by modifying the reaction conditions, thus we examined various aerobic oxidation conditions, as shown in Table 1. However, the use of K₂CO₃, DBU, and TBAF (entries 1-3) afforded similar yields of products (60-67%), while the use of imidazole and pyridine was not effective (entries 4 and 5). Solvent effect was also negligible (entries 6-8), unfortunately. Although the difference is small we chose the conditions in entry 7 as the optimum one based on the combined yields.







Scheme 1

Entry	Conditions ^a	2a $(\%)^b$ / 3a $(\%)^b$
1	K ₂ CO ₃ (3.0 equiv), DMF, rt, 3 h	25 / 35
2	DBU (3.0 equiv), DMF, rt, 3 h	29/38
3	TBAF (3.0 equiv), THF, rt, 3 h	24 / 40
4	Imidazole (3.0 equiv), DMF, rt, 24 h	trace / trace
5	pyridine, 100 °C 12 h	0 / 0
6	DBU (3.0 equiv), CH ₃ CN, rt, 3 h	20/31
7	DBU (2.0 equiv), CH ₂ Cl ₂ , rt, 5 h	27 / 48
8	DBU (0.5 equiv), DMF, rt, 5 h	23 / 40

 Table 1. Oxidation of 1a under various conditions

^{*a*}Carried out under O₂ balloon. ^{*b*}Isolated yield.

In order to check the generality, starting materials **1b-h** were prepared^{1,2} and examined an aerobic oxidation under the optimum conditions. The results are summarized in Table 2. In the reactions of 6-aryl derivatives (entries 1-5), the yields of catechol derivatives **2a-e** were low (19-27%), while the yields of C-1 oxidation products **3a-e** were moderate (45-52%). The reaction of 6-pentyl derivative **1f** produced **3f** (59%) as a major product (entry 6). Trace amount of **2f** was observed on TLC; however, we could not obtain **2f** in appreciable amounts. The reaction of 6-methyl derivative **1g** also afforded **3g** (61%) as a major product (entry 7), and this result is similar to that of Irie.^{3a} Quite surprisingly, the reaction of **1h** produced catechol **2h** as a major product in moderate yield (47%, entry 8). The different

Table 2. DBU-mediated aerobic oxidation of Hagemann's ester



Figure 2. NOE results of compound 3d.

reactivity of **1h** is not clear at this stage.⁵

It is interesting to note that compounds **3a-f** were obtained as single diastereomers although we used *cis/trans* mixtures of **1a-f**.^{3a} The only exception was 6-methyl derivative **3g** (entry 7). A trace amount of the other diastereomer was contaminated (*ca.* 10%). The stereochemistry of **3a-f** is thought to be as that shown in Figure 2, tentatively.⁶ NOE experimental results with **3d** stated that the substituent at C-6 and an ester moiety are positioned in a *cis*-relationship.

A useful synthetic application of C-1 oxidation products was demonstrated in Scheme 2, with **3a** as a representative example.⁷ Treatment of **3a** with NaI in DMSO (120 °C, 30 min) produced **5a** *via* NaI/O₂-assisted concomitant dealkoxycarbonylation/aerobic oxidation.⁸

In summary, we examined an aerobic oxidation of various Hagemann's ester under the influence of DBU in CH₂Cl₂. Hydroxylation at C-1 position is favored to produce 1-



^{*a*}Conditions: aldehyde (2.0 mmol), methyl acetoacetate (2.5 equiv), piperidine (0.5 equiv), MeOH, reflux, 5 h. ^{*b*}Conditions: DBU (2.0 equiv), CH₂Cl₂, rt, 5 h, O₂ balloon. ^{*c*}Ar¹ is 4-MePh. ^{*d*}Ar² is 4-MeOPh. ^{*e*}Ar³ is 4-CIPh. ^{*f*}Ethyl acetoacetate was used. ^{*g*}Failed to isolate. ^{*b*}Conditions: rt, 2 days. ^{*f*}Trace amount (*ca.* 10%) of the other stereoisomer was mixed.



Notes

hydroxycyclohexenone derivatives in moderate yields, while hydroxylation at C-3 position occurred as a minor pathway.

Experimental Section

Typical Procedure for the Preparation of 1a. A stirred solution of benzaldehyde (212 mg, 2.0 mmol), methyl aceto-acetate (580 mg, 5.0 mmol), and piperidine (85 mg, 1.0 mmol) in MeOH (6 mL) was heated to reflux for 5 h. After aqueous extractive workup and column chromatographic purification process (hexanes/EtOAc, 6:1) compound **1a** was isolated a white solid, 342 mg (70%).^{1b,1e,2c,2h} Other Hagemann's esters (**1b-d**, **1e**,^{2d-g} **1f**,^{2j} **1g**,^{2c} **1h**^{2d-g}) were prepared similarly, and the spectroscopic data of unknown compounds, **1b-d** are as follows.

Compound 1b: 60%; white solid, mp 101-102 °C; IR (KBr) 1737, 1674, 1632, 1435 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.96 (s, 3H), 2.32 (s, 3H), 2.57-2.74 (m, 2H), 3.55-3.68 (m, 2H), 3.61 (s, 3H), 6.05 (s, 1H), 7.09 (d, *J* = 8.7 Hz, 2H), 7.12 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 21.00, 22.42, 42.67, 43.42, 52.15, 54.34, 126.90, 128.37, 129.43, 137.02, 137.83, 155.97, 171.85, 197.39; ESIMS *m*/z 259 (M⁺+H).

Compound 1c: 61%; white solid, mp 74-75 °C; IR (KBr) 1736, 1672, 1612, 1514, 1436, 1254 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.96 (s, 3H), 2.56-2.73 (m, 2H), 3.53-3.66 (m, 2H), 3.60 (s, 3H), 3.79 (s, 3H), 6.05 (s, 1H), 6.85 (d, *J* = 8.4 Hz, 2H), 7.13 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 22.36, 42.84, 43.12, 52.13, 54.54, 55.16, 114.06, 128.07, 128.36, 132.88, 156.03, 158.68, 171.88, 197.39; ESIMS *m/z* 275 (M⁺+H).

Compound 1d: 59%; white solid, mp 106-107 °C; IR (KBr) 1735, 1669, 1631, 1492, 1435 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.97 (s, 3H), 2.55-2.74 (m, 2H), 3.54-3.70 (m, 2H), 3.62 (s, 3H), 6.06 (s, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 22.35, 42.38, 43.17, 52.22, 53.99, 128.37, 128.44, 128.92, 133.13, 139.31, 155.72, 171.52, 196.67; ESIMS *m/z* 279 (M⁺+H), 281 (M⁺+2+H).

Typical Procedure for the Synthesis of 2a and 3a. To a stirred solution of 1a (244 mg, 1.0 mmol) in CH_2Cl_2 (2 mL) was added DBU (304 mg, 2.0 mmol), and the reaction mixture was stirred at room temperature for 5 h under O₂ balloon atmosphere. After aqueous extractive workup and column chromatographic purification process (hexanes/EtOAc, 4:1) compounds 2a (70 mg, 27%) and 3a (126 mg, 48%) were isolated. Other entries were carried out similarly, and the spectroscopic data of unknown compounds, 2a-e, 2h and 3a-g are as follows.

Compound 2a: 27%; pale yellow oil; IR (film) 3397, 1697, 1611, 1489 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.26 (s, 3H), 3.55 (s, 3H), 5.49 (br s, 1H), 6.08 (br s, 1H), 6.68 (s, 1H), 7.25-7.36 (m, 5H); ¹³C NMR (CDCl₃, 75 MHz) δ 12.76, 52.06, 114.03, 122.75, 126.07, 127.01, 128.04, 128.20, 133.09, 140.70, 141.67, 144.14, 171.04; ESIMS *m*/*z* 259 (M⁺+H). Anal. Calcd for C₁₅H₁₄O₄: C, 69.76; H, 5.46. Found: C, 69.99; H, 5.62.

Compound 3a: 48%; white solid, mp 117-118 °C; IR (KBr) 3495, 1736, 1670, 1437, 1234 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.94 (s, 3H), 2.65 (dd, J = 16.8 and 4.5 Hz, 1H), 3.35 (dd, J = 16.8 and 14.7 Hz, 1H), 3.64 (dd, J = 14.7 and 4.5 Hz,

1H), 3.77 (s, 3H), 3.82 (s, 1H), 6.10 (s, 1H), 7.18-7.21 (m, 2H), 7.29-7.33 (m, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 18.86, 39.79, 50.15, 53.55, 78.89, 128.03, 128.26, 128.47, 129.29, 136.92, 158.60, 172.23, 197.79; ESIMS *m*/*z* 261 (M⁺+H). Anal. Calcd for C₁₅H₁₆O₄: C, 69.22; H, 6.20. Found: C, 69.51; H, 6.07.

Compound 2b: 19%; white solid, mp 164-166 °C; IR (KBr) 3131, 1719, 1604, 1501, 1299 cm⁻¹; ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) δ 2.26 (s, 3H), 2.35 (s, 3H), 3.56 (s, 3H), 6.60 (br s, 1H), 6.75 (s, 1H), 7.13 (d, *J* = 8.4 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 8.70 (br s, 1H); ¹³C NMR (CDCl₃ + DMSO-*d*₆, 75 MHz) δ 12.79, 20.97, 51.58, 114.03, 122.59, 125.49, 127.82, 128.74, 132.23, 136.20, 138.18, 141.99, 144.76, 170.46; ESIMS *m/z* 273 (M⁺+H). Anal. Calcd for C₁₆H₁₆O₄: C, 70.57; H, 5.92. Found: C, 70.34; H, 6.05.

Compound 3b: 47%; white solid, mp 110-111 °C; IR (KBr) 3367, 1736, 1666, 1434, 1235 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.93 (s, 3H), 2.33 (s, 3H), 2.62 (dd, *J* = 16.8 and 4.5 Hz, 1H), 3.32 (dd, *J* = 16.8 and 14.7 Hz, 1H), 3.59 (dd, *J* = 14.7 and 4.5 Hz, 1H), 3.68 (s, 1H), 3.77 (s, 3H), 6.08 (s, 1H), 7.07 (d, *J* = 8.1 Hz, 2H), 7.13 (d, *J* = 8.1 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 18.86, 20.99, 39.89, 49.80, 53.49, 78.91, 128.07, 129.15, 129.25, 133.84, 137.67, 158.63, 172.29, 197.93; ESIMS *m*/*z* 275 (M⁺+H). Anal. Calcd for C₁₆H₁₈O₄: C, 70.06; H, 6.61. Found: C, 70.17; H, 6.93.

Compound 2c: 24%; pale yellow oil; IR (film) 3398, 1699, 1610, 1499, 1293 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.22 (s, 3H), 3.59 (s, 3H), 3.79 (s, 3H), 5.76 (br s, 1H), 6.59 (s, 1H), 6.81 (br s, 1H), 6.83 (d, *J* = 8.7 Hz, 2H), 7.13 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 12.74, 52.09, 55.22, 113.65, 113.93, 122.56, 125.93, 129.12, 132.48, 133.20, 141.47, 144.18, 158.60, 171.27; ESIMS *m/z* 289 (M⁺+H). Anal. Calcd for C₁₆H₁₆O₅: C, 66.66; H, 5.59. Found: C, 66.43; H, 5.72.

Compound 3c: 45%; white solid, mp 113-114 °C; IR (KBr) 3490, 1735, 1672, 1612, 1513, 1438, 1257 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.93 (s, 3H), 2.61 (dd, J = 16.8 and 4.5 Hz, 1H), 3.30 (dd, J = 16.8 and 14.7 Hz, 1H), 3.57 (dd, J = 14.7 and 4.5 Hz, 1H), 3.72 (s, 1H), 3.77 (s, 3H), 3.78 (s, 3H), 6.08 (s, 1H), 6.85 (d, J = 8.7 Hz, 2H), 7.12 (d, J = 8.7 Hz, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 18.83, 39.98, 49.33, 53.45, 55.08, 78.95, 113.75, 128.84, 129.21 (2C), 158.61, 159.15, 172.23, 197.89; ESIMS *m*/*z* 291 (M⁺+H). Anal. Calcd for C₁₆H₁₈O₅: C, 66.19; H, 6.25. Found: C, 66.45; H, 6.51.

Compound 2d: 23%; pale yellow solid, mp 156-158 °C; IR (KBr) 3384, 1718, 1603, 1486, 1304 cm⁻¹; ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) δ 2.25 (s, 3H), 3.59 (s, 3H), 5.46 (br s, 1H), 5.95 (br s, 1H), 6.63 (s, 1H), 7.17 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (CDCl₃ + DMSO*d*₆, 75 MHz) δ 12.70, 51.51, 113.81, 122.84, 125.22, 127.99, 129.21, 130.72, 132.42, 139.61, 142.38, 144.88, 169.97; ESIMS *m*/*z* 293 (M⁺+H), 295 (M⁺+2+H). Anal. Calcd for C₁₅H₁₃ClO₄: C, 61.55; H, 4.48. Found: C, 61.49; H, 4.41.

Compound 3d: 48%; white solid, mp 98-99 °C; IR (KBr) 3497, 1735, 1670, 1492, 1246 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.93 (s, 3H), 2.63 (dd, J = 16.8 and 4.8 Hz, 1H), 3.29 (dd, J = 16.8 and 14.4 Hz, 1H), 3.62 (dd, J = 14.4 and 4.8 Hz, 1H), 3.70 (s, 1H), 3.78 (s, 3H), 6.09 (s, 1H), 7.14 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H); ¹³C NMR (CDCl₃,

75 MHz) δ 18.84, 39.67, 49.35, 53.74, 78.73, 128.65, 129.29, 129.64, 133.93, 135.46, 158.51, 172.19, 197.29; ESIMS *m*/*z* 295 (M⁺+H), 297 (M⁺+2+H). Anal. Calcd for C₁₅H₁₅ClO₄: C, 61.13; H, 5.13. Found: C, 61.47; H, 5.44.

Compound 2e: 24%; pale yellow oil; IR (film) 3386, 1690, 1608, 1488, 1300 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.94 (t, *J* = 7.2 Hz, 3H), 2.24 (s, 3H), 4.03 (q, *J* = 7.2 Hz, 2H), 5.74 (br s, 1H), 6.58 (s, 1H), 6.69 (br s, 1H), 7.18-7.32 (m, 5H); ¹³C NMR (CDCl₃, 75 MHz) δ 12.70, 13.50, 61.46, 114.02, 122.70, 125.94, 126.94, 128.09, 128.16, 133.11, 140.73, 141.70, 144.18, 171.01; ESIMS *m/z* 273 (M⁺+H).

Compound 3e: 52%; pale yellow oil; IR (film) 3495, 1731, 1672, 1453, 1234 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.27 (t, J = 7.2 Hz, 3H), 1.94 (s, 3H), 2.65 (dd, J = 16.5 and 4.2 Hz, 1H), 3.37 (dd, J = 16.5 and 14.7 Hz, 1H), 3.64 (dd, J = 14.7 and 4.2 Hz, 1H), 3.73 (s, 1H), 4.21 (q, J = 7.2 Hz, 2H), 6.10 (s, 1H), 7.21-7.35 (m, 5H); ¹³C NMR (CDCl₃, 75 MHz) δ 14.00, 18.78, 39.78, 49.93, 63.20, 78.63, 127.92, 128.34, 128.36, 129.11, 136.88, 158.93, 171.63, 197.93; ESIMS *m/z* 275 (M⁺+H).

Compound 3f: 59%; pale yellow oil; IR (film) 3500, 1732, 1670, 1437, 1229 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.88 (t, *J* = 6.9 Hz, 3H), 1.17-1.42 (m, 7H), 1.68-1.79 (m, 1H), 1.90 (s, 3H), 2.23-2.34 (m, 1H), 2.46 (dd, *J* = 16.8 and 13.5 Hz, 1H), 2.63 (dd, *J* = 16.8 and 5.1 Hz, 1H), 3.84 (s, 3H), 4.02 (s, 1H), 6.00 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.90, 18.66, 22.39, 26.37, 29.62, 31.54, 39.46, 43.83, 53.63, 78.05, 129.28, 159.49, 173.52, 197.97; ESIMS *m*/*z* 255 (M⁺+H). Anal. Calcd for C₁₄H₂₂O₄: C, 66.12; H, 8.72. Found: C, 66.44; H, 8.56.

Compound 3g: 61%; white solid, mp 89-90 °C; IR (KBr) 3389, 1739, 1657, 1434, 1237 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.00 (d, *J* = 6.0 Hz, 3H), 1.91 (s, 3H), 2.42-2.65 (m, 3H), 3.86 (s, 3H), 4.06 (s, 1H), 6.00 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 15.42, 18.65, 39.03, 42.14, 53.63, 78.45, 129.39, 159.31, 173.29, 197.87; ESIMS *m*/*z* 199 (M⁺+H). Anal. Calcd for C₁₀H₁₄O₄: C, 60.59; H, 7.12. Found: C, 60.42; H, 7.34.

Compound 2h: 47%; pale yellow solid, mp 160-161 °C; IR (KBr) 3119, 1710, 1611, 1585, 1435, 1298 cm⁻¹; ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) d 2.50 (s, 3H), 3.83 (s, 3H), 6.70 (br s, 1H), 6.73 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 8.90 (br s, 1H); ¹³C NMR (CDCl₃ + DMSO-*d*₆, 75 MHz) d 12.94, 51.38, 111.58, 121.82, 123.23, 127.23, 142.98, 147.49, 168.08; ESIMS *m*/*z* 183 (M⁺+H). Anal. Calcd for C₉H₁₀O₄: C, 59.34; H, 5.53. Found: C, 59.56; H, 5.78.

Synthesis of Compound 5a. To a stirred solution of **3a** (104 mg, 0.4 mmol) in DMSO (1 mL) was added NaI (180 mg, 1.2 mmol), and the reaction mixture was heated to 120 °C for 30 min. After aqueous extractive workup and column chromatographic purification process (hexanes/EtOAc, 4:1) compounds **5a** was isolated, 45 mg (56%).

Compound 5a: yellow oil; IR (film) 3444, 1711, 1602, 1468, 1430 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.25 (s, 3H), 4.75 (br s, 1H), 4.91 (br s, 1H), 6.56 (d, *J* = 2.7 Hz, 1H), 6.64 (d, *J* = 2.7 Hz, 1H), 7.38-7.50 (m, 5H); ¹³C NMR (CDCl₃, 75 MHz) δ 16.37, 113.94, 117.28, 125.94, 127.90, 128.23, 128.99, 129.27, 137.15, 144.51, 148.56; ESIMS *m/z*

Acknowledgments. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0015675). Spectroscopic data were obtained from the Korea Basic Science Institute, Gwangju branch.

References and Notes

- For the synthesis of Hagemann's ester and related compounds, see: (a) Pollini, G. P.; Benetti, S.; De Risi, C.; Zanirato, V. *Tetrahedron* 2010, 66, 2775-2802 and further references cited therein. (b) Kingsbury, C. A.; Egan, R. S.; Perun, T. J. J. Org. Chem. 1970, 35, 2913-2918. (c) Gassama, A.; d'Angelo, J.; Cave, C.; Mahuteau, J.; Riche, C. *Eur. J. Org. Chem.* 2000, 3165-3169. (d) Nour, M.; Tan, K.; Jankowski, R.; Cave, C. *Tetrahedron: Asymmetry* 2001, 12, 765-769. (e) Nitta, H.; Takimoto, K.; Ueda, I. *Chem. Pharm. Bull.* 1992, 40, 858-863. (f) Yang, Y.-Q.; Chai, Z.; Wang, H.-F.; Chen, X.-K.; Cui, H.-F.; Zheng, C.-W.; Xiao, H.; Li, P.; Zhao, G. *Chem. Eur. J.* 2009, 13, 13295-13298.
- For the synthetic applications of Hagemann's ester, see: (a) Srikrishna, A.; Ramachary, D. B. *Tetrahedron Lett.* 2000, *41*, 2231-2233. (b) Banerjee, M.; Mukhopadhyay, R.; Achari, B.; Banerjee, A. K. *Synthesis* 2006, 1263-1272. (c) Majetich, G; Allen, S. *ARKIVOC* 2010, *iv*, 104-124. (d) Ramachary, D. B.; Ramakumar, K.; Narayana, V. V. *J. Org. Chem.* 2007, *72*, 1458-1463. (e) Ramachary, D. B.; Ramakumar, K.; Narayana, V. V. *Chem. Eur. J.* 2008, *14*, 9143-9147. (f) Ramachary, D. B.; Narayana, V. V.; Ramakumar, K. *Eur. J. Org. Chem.* 2008, 3907-3911. (g) Ramachary, D. B.; Narayana, V. V.; Prasad, M. S.; Ramakumar, K. *Org. Biomol. Chem.* 2009, *7*, 3372-3378. (h) Niwas, S.; Bhaduri, A. P. *Synthesis* 1983, 110-111. (i) Kotnis, A. S. *Tetrahedron Lett.* 1990, *31*, 481-484. (j) Trost, B. M.; Fortunak, J. M. *J. Am. Chem. Soc.* 1980, *102*, 2841-2843.
- For the oxidation of Hagemann's ester, see: (a) Irie, H.; Katakawa, J.; Tomita, M.; Mizuno, Y. *Chem. Lett.* **1981**, 637-640. (b) Sriyani Ananda, G D.; Cremins, P. J.; Stoodley, R. J. *J. Chem. Soc., Chem. Commun.* **1987**, 882-883.
- For our recent results on aerobic oxidation, see: (a) Kim, K. H.; Lee, H. S.; Kim, S. H.; Lee, K. Y.; Lee, J.-E.; Kim, J. N. *Bull. Korean Chem. Soc.* 2009, *30*, 1012-1020. (b) Kim, J. M.; Lee, S.; Kim, S. H.; Lee, H. S.; Kim, J. N. *Bull. Korean Chem. Soc.* 2008, *29*, 2215-2220. (c) Lee, H. S.; Kim, J. M.; Kim, J. N. *Tetrahedron Lett.* 2007, *48*, 4119-4122. (d) Kim, S. C.; Lee, K. Y.; Lee, H. S.; Kim, J. N. *Tetrahedron* 2008, *64*, 103-109. (e) Park, D. Y.; Lee, K. Y.; Gowrisankar, S.; Kim, J. N. *Bull. Korean Chem. Soc.* 2008, *29*, 701-704. For recent examples of aerobic oxidation by other groups, see: (f) Huang, Y.; Gan, H.; Li, S.; Xu, J.; Wu, X.; Yao, H. *Tetrahedron Lett.* 2010, *51*, 1751-1753.
- When we repeated the reaction of Stoodley (activated charcoal, EtOAc, reflux, 24 h), C-1-oxidation product was formed as the major one, as reported.^{3b}
- 6. Trials for obtaining a crystal for X-ray diffraction failed. $^{\mbox{\tiny 3a}}$
- For the synthesis and synthetic applications of 1-substituted Hagemann's ester derivatives, see: (a) Cui, H.-F.; Yang, Y.-Q.; Chai, Z.; Li, P.; Zheng, C.-W.; Zhu, S.-Z.; Zhao, G. J. Org. Chem. **2010**, 75, 117-122. (b) Jung, M. E.; Novack, A. R. Tetrahedron Lett. **2005**, 46, 8237-8240. (c) Jung, M. E.; Nishimura, N.; Novack, A. R. J. Am. Chem. Soc. **2005**, 127, 11206-11207. (d) Shapland, P. D. P.; Thomas, E. J. Tetrahedron **2009**, 65, 4201-4211.
- For NaI/O₂-assisted concomitant dealkoxycarbonylation/aerobic oxidation, see: (a) Lee, H. S.; Kim, S. H.; Kim, Y. M.; Kim, J. N. *Tetrahedron Lett.* **2010**, *51*, 5071-5075. (b) Im, Y. J.; Lee, K. Y.; Kim, T. H.; Kim, J. N. *Tetrahedron Lett.* **2002**, *43*, 4675-4678. (c) Santi, R.; Bergamini, F.; Citterio, A.; Sebastiano, R.; Nicolini, M. *J. Org. Chem.* **1992**, *57*, 4250-4255.